Zargo

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zargo

Quick Facts

Property Description
Active ingredient Losartan (Losartan potassium)
Form Oral Tablet, Oral Suspension
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Lowering of blood pressure
Origin Synthetic, non-peptide compound

What is Zargo, and what is its Pharmacological Class?

Zargo is a prescription-only medication whose active ingredient is Losartan, typically compounded as Losartan potassium. It is formally classified as an Angiotensin II Receptor Blocker (ARB) for managing cardiovascular health. This pharmacological class places Zargo among the primary agents used in the management of high blood pressure and other cardiovascular conditions. Unlike older ACE Inhibitors, which suppress the formation of Angiotensin II, Losartan acts as a selective AT1 receptor antagonist, directly blocking the activity of Angiotensin II and its role as a potent vasoconstrictor. Losartan functions by inhibiting a specific receptor in the body’s blood pressure regulatory system.

Composition, Form, and Origin of Losartan

The Losartan molecule is a synthetic, non-peptide compound, differentiating it from compounds derived from natural peptides. The medication is most frequently administered via the oral route as a film-coated oral tablet. As a single-ingredient product, the composition consists of the active ingredient Losartan potassium combined with various solid pharmaceutical excipients. Losartan is structurally unique among its class. For specific patient groups, such as children older than six, Losartan can also be prepared as an oral suspension. Losartan is an orally effective drug used to treat hypertension.

What is the General Purpose of an Angiotensin II Receptor Blocker?

The general purpose of Zargo is to reduce the strain on the cardiovascular system by facilitating the relaxation and widening of blood vessels. This mechanism helps diminish the effects that lead to elevated vascular tension. By effectively easing the resistance to blood flow, Zargo's general function is the consistent and successful lowering of blood pressure, which is its fundamental therapeutic application, often used when patients require continuous management of their vascular tone.

What side effects are possible with Zargo?

Possible Side Effects and Safety Information

Common Adverse Reactions

Frequencies are based on regulatory documentation from clinical trials and post-marketing surveillance. The most common side effects reported with Zargo include dizziness, back pain, upper respiratory tract infection, nasal congestion, and cough.

Less commonly, patients may experience fatigue, diarrhea, stomach pain, difficulty urinating, or general weakness.

Serious and Clinically Significant Risks

  • Hypersensitivity: Immediate medical attention is required for signs of serious allergic reactions, such as swelling of the face, lips, tongue, and/or throat (angioedema), severe dizziness, or difficulty breathing.
  • Hypotension: The medicine can cause low blood pressure, which may lead to dizziness or fainting, particularly when rising from a sitting or lying position.
  • Hyperkalaemia: Zargo may increase blood potassium levels (hyperkalaemia), which can affect heart rhythm. Monitoring of potassium levels is often required.
  • Kidney Function: The drug may adversely affect kidney function, especially in patients with pre-existing kidney disease or severe heart failure. Close monitoring of kidney health is necessary during treatment.

Safety Restrictions and Monitoring

Category Safety Statement
Contraindications Contraindicated during pregnancy due to risk of fetal harm, in severe liver impairment, and with co-administration of aliskiren in patients with diabetes or moderate-to-severe kidney impairment.
High-Risk Populations Caution is advised in patients with pre-existing kidney or liver problems, heart failure, and those who are volume-depleted or have a history of angioedema.
General Monitoring Regular monitoring of blood pressure, kidney function, and serum potassium levels is required throughout the course of therapy.
Alertness Avoid driving or operating heavy machinery if dizziness or drowsiness is experienced.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose exposure to Zargo (Losartan) is derived strictly from official government regulatory sources, detailing documented clinical manifestations and mandated emergency actions.

Documented Overdose Manifestations

The primary clinical signs of Zargo overdose are direct consequences of an exaggerated blood pressure-lowering effect, most commonly presenting as hypotension (clinically significant low blood pressure). Overdose may also result in disturbances to cardiac rhythm, specifically documented as tachycardia (fast heart rate) or, less frequently, bradycardia (slow heart rate due to vagal stimulation).

Severe outcomes associated with acute overdose include symptoms related to profound hypotension, such as dizziness and fainting. More serious manifestations that require immediate medical attention are collapse, seizure, trouble breathing, or the inability to be awakened.

Emergency Actions and Management

Official guidance mandates that the poison control helpline must be called following suspected overdose exposure. However, if severe symptoms like collapse, a seizure, trouble breathing, or unconsciousness are present, emergency medical services must be contacted immediately.

Management of overdose is symptomatic and supportive, focusing on instituting appropriate treatment for symptomatic hypotension. It is officially noted that no specific antidote is documented for Losartan, and due to its high protein binding, the drug is not expected to be removed by hemodialysis.

Therapeutic Uses of Zargo

What Zargo Treats: Main Uses and Benefits

Zargo is indicated for the symptomatic management of specific health conditions, focusing on providing relief from burdensome symptoms. Its primary therapeutic domains include supporting individuals experiencing mild to moderate pain and addressing manifestations of local inflammation and swelling. The medicine is commonly used in clinical scenarios involving temporary musculoskeletal discomfort, such as in the short-term relief of pain associated with minor injuries or managing symptoms during flares of certain chronic inflammatory conditions.

The core benefit of Zargo is to assist in the alleviation of symptom severity, which may support improved functionality and enhance a patient's capacity to engage in routine daily activities. The medicine is part of a standard approach to care for these indications.


Quick Fact: Symptomatic Relief

Zargo is used to assist in the management of pain, discomfort, and inflammation related to muscle and joint issues.


Eligibility and Restrictions for Use

Who Can and Cannot Use Zargo? (Official Eligibility Rules)

Official regulatory documents strictly define the patient populations eligible to use Zargo (Losartan).

Eligibility Status Patient Population/Condition
Contraindicated Pregnancy (due to Fetal Toxicity risk); Known hypersensitivity to Losartan; Patients with diabetes mellitus who are concurrently taking aliskiren (Do not co-administer)
Not Recommended Children under 6 years of age; Pediatric patients with a glomerular filtration rate (GFR) less than 30 mL/min/1.73 m²; Mothers who are breastfeeding
Conditional Use Patients with mild-to-moderate hepatic impairment require a lower initial dose; Patients with volume- or salt-depletion must have their condition corrected before initiating use

Eligibility for Zargo is established for adults and children aged 6 to 16 years for the approved indications. The use in pregnancy is an absolute prohibition. The official label also notes that the benefit of stroke reduction for a specific cardiovascular condition may not apply to Black patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Losartan, the active ingredient in Zargo, has officially documented interaction patterns that are classified based on pharmacokinetic (PK) and pharmacodynamic (PD) effects, as detailed in regulatory labeling.

Documented Pharmacodynamic Interactions

Co-administration with Potassium-sparing diuretics (such as spironolactone) or potassium supplements carries a high risk of hyperkalemia (elevated serum potassium levels) due to an additive PD effect. The concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may increase the risk of acute renal function deterioration and can reduce Losartan's primary antihypertensive effect. Additionally, Losartan can reduce the renal clearance of Lithium, increasing the risk of lithium toxicity.

Pharmacokinetic and Restriction Notes

Certain substances formally alter Losartan's plasma exposure. The drug Fluconazole (a CYP2C9 inhibitor) significantly increases the exposure of Losartan, while the enzyme inducer Rifampin reduces the exposure of both Losartan and its active metabolite. Dual blockade of the Renin-Angiotensin System (RAS) with Aliskiren is officially contraindicated in patients with Type 2 diabetes due to heightened risks of hyperkalemia and renal impairment. Furthermore, regulatory documents note that in patients with hepatic impairment, Losartan's exposure is substantially increased, amplifying potential interaction effects.

Mechanism of Action

Zargo is a selective estrogen receptor modulator (SERM). Its pharmacodynamic activity is mediated through targeting estrogen receptors alpha and beta. Zargo exhibits tissue-selective modulation by acting as an agonist in bone tissue receptors, while simultaneously acting as an antagonist in breast tissue receptors.

In bone, agonist binding activates intracellular signaling pathways that lead to a reduction of osteoclast activity and a corresponding shift toward osteoblast-mediated bone formation. This mechanistic action results in the modulation of bone turnover markers and alters the expression of genes involved in bone matrix composition.

The antagonistic effect in breast tissue involves competitive binding to the estrogen receptor, which modulates the downstream transcription of estrogen-responsive genes. The overall molecular cascade involves Zargo's receptor binding, subsequent nuclear translocation, and the resulting tissue-specific modulation of gene transcription in target cell nuclei.

Dosage and Administration Information

How to Use Zargo

Zargo, containing the active ingredient Losartan, is administered via the oral route as part of a long-term plan for managing chronic conditions. The medication is supplied primarily as a film-coated oral tablet in strengths including 25 mg, 50 mg, and 100 mg.

Administration Protocol

Entity Guideline
Route of administration Oral (by mouth)
Dosing schedule Standard start 50 mg Q.D.; maintenance 25 mg to 100 mg Q.D.
Timing in relation to meals Can be administered with or without food.
Preparation requirements Oral suspension for pediatrics must be compounded from tablets.
Age-group administration Pediatric dosing is weight-based; maximum dose is 50 mg daily.

The consistent pattern of use for Zargo involves administration once daily. The typical adult regimen begins with a starting dose of 50 mg once daily, which may be adjusted upward after three to six weeks to establish the required level. The maximum recommended daily dose is 100 mg.

Population-Specific Use Principles

Patients with hepatic impairment or those with intravascular volume depletion typically begin therapy with a reduced starting dose of 25 mg once daily. This is a principle of use designed to standardize administration in individuals with altered systemic handling capacity. Losartan is intended for chronic, sustained use, defining its role as a foundational medicine rather than an intermittent or short-term course.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zargo

Research for Zargo (Losartan) is primarily derived from large, randomized controlled trials (RCTs) and long-term studies that investigated its use for high blood pressure and related conditions, particularly where patients had high cardiovascular or kidney risk. The evidence describes group patterns observed in these studies, but research does not determine whether an individual will respond similarly.


Evidence for use in Essential Hypertension (High Blood Pressure)

Researchers conducted numerous short-term RCTs to examine Losartan's use for essential hypertension, focusing on measuring the change in Systolic and Diastolic Blood Pressure (BP). Short-term trials reported measurements where data show patterns related to blood pressure changes in the Losartan groups compared to placebo groups. While research exploring short-term symptom patterns is available across multiple trials, long-term outcomes for essential hypertension alone are often characterized by data from high-risk populations.


Evidence for use in Cardiovascular and Stroke Risk Reduction

Research in this area involved large, long-term RCTs that specifically enrolled high-risk hypertensive patients, such as those with Left Ventricular Hypertrophy (LVH). Studies monitored a composite cardiovascular endpoint (including stroke and heart attack). Studies reported measurements where findings describe patterns observed in the studies related to the primary composite endpoint compared to the group receiving the beta-blocker used as a comparator. The evidence remains specific to the high-risk population with LVH studied in the key clinical trials.


Research for Kidney Health in Diabetes

Losartan was studied for patients with Type 2 Diabetes Mellitus who had clear markers of kidney impairment, such as protein in the urine (proteinuria). The primary endpoint was the progression of renal disease (including the need for dialysis or transplant). Trials reported patterns observed where the proportion of patients who reached the primary composite endpoint was numerically different in the Losartan group compared to the placebo group. Research primarily focused on patients with Type 2 Diabetes and established nephropathy.


Evidence Gaps and Areas of Scientific Uncertainty

Comparative evidence is lacking for Losartan against all newer anti-hypertensive drugs for specific long-term cardiovascular outcomes. Subgroup findings were uncertain for Black patients in the major event-reduction trials. Evidence consistency varies across studies when examining secondary or exploratory outcomes, and data for very long-term outcomes (many years) remain limited.

Frequently Asked Questions (FAQ)

Common questions about Zargo (FAQ)


Q: How does Zargo work to protect the kidneys in people with diabetes?

Studies and official information indicate that Zargo (Losartan) is indicated to slow the progression of renal disease in patients with Type 2 diabetes who have evidence of kidney impairment (proteinuria). This clinical benefit has been demonstrated in large, randomized trials that monitored the progression of renal disease.


Q: What is the difference between Zargo and a water pill (diuretic)?

Zargo is classified as an Angiotensin II Receptor Blocker (ARB). It works by blocking a hormone called Angiotensin II to help relax and widen blood vessels. Diuretics, often called 'water pills,' are a different class of medication that primarily works to help the body remove excess salt and water through increased urination.


Q: How long does it typically take to see the full blood pressure lowering effect of Zargo?

Regulatory information indicates that the full blood pressure-lowering effect of Zargo is typically reached within three to six weeks after starting the medicine or adjusting the dose. While an initial reduction may be observed sooner, its full therapeutic benefit is generally achieved after several weeks.


Q: Is it normal to feel a bit dizzy or lightheaded when first starting Zargo?

Dizziness is a common side effect of Zargo reported in clinical trials. As a blood pressure medicine, it can sometimes cause low blood pressure (hypotension), which might cause lightheadedness, particularly when getting up quickly from a sitting or lying position.


Q: Can Zargo cause a change in blood potassium levels?

Official product information states that Zargo may cause an increase in blood potassium levels (hyperkalemia). This is why regulatory guidance often requires regular monitoring of serum potassium levels during the course of treatment.


Q: What are the less common, but important, side effects of Zargo that I should know about?

Regulatory documents report that less common side effects can include fatigue, diarrhea, stomach pain, difficulty urinating, and general weakness. Patients are advised to be aware of the serious and clinically significant risks, such as allergic reactions or severe drops in blood pressure, as detailed in the drug's safety information.


Q: Does Zargo interact with common over-the-counter pain relievers like Ibuprofen or NSAIDs?

Yes, regulatory documents warn that Zargo can interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes medicines like ibuprofen. The concurrent use of these products may increase the risk of acute kidney function issues and can reduce Zargo's effect of lowering blood pressure.


Q: Is it normal for Zargo to cause an increase in coughing, or is that a side effect of a different class of medicine?

Cough is listed as a common adverse reaction for Zargo in its official labeling. While coughing is frequently associated with a different class of blood pressure medicine (ACE inhibitors), it is also a possibility when taking Zargo (Losartan).


Q: Does Zargo's effectiveness decrease over time?

Regulatory documents indicate that the effect of Zargo was maintained for long periods in follow-up studies, supporting its chronic use. The drug is intended for sustained, long-term management of chronic conditions.


Q: If I have a history of angioedema, is Zargo a safe option for me?

Official safety information advises caution in patients with a history of swelling of the face, lips, or throat (angioedema). This serious reaction is a possible side effect of Zargo, and caution is advised in patients with this history.


Q: Does Zargo affect a person's ability to operate machinery or drive?

Because Zargo can cause dizziness or drowsiness, which could affect concentration, it is advised that driving or operating heavy machinery should be avoided if those side effects are experienced.


Q: Is Zargo used for people who only have mildly elevated blood pressure?

Zargo is indicated for the treatment of hypertension, which is the clinical term for high blood pressure. Studies used to support its approval were conducted on patients with essential hypertension, but the official label does not specify the minimum level of elevation required for its use.


Q: What is the angiotensin II receptor blocker (ARB) class of medicine, and how does Zargo fit into it?

The ARB class, to which Zargo belongs, is a group of medicines that selectively block the binding of the hormone Angiotensin II to the AT1 receptor. This action prevents the blood vessels from constricting, which helps to lower blood pressure.


Q: What is the difference between Losartan (the active ingredient in Zargo) and other ARBs?

Losartan is one of several medicines in the ARB class. While all ARBs block the same Angiotensin II receptor, Losartan has a unique structure and its active metabolite is described in official documents as having a specific binding profile compared to some other ARBs.


Q: Can Zargo cause fatigue or tiredness that might affect my daily energy level?

Official labeling lists fatigue and general weakness as less common side effects reported in clinical trials. If experienced, these effects could potentially impact daily energy levels.


Q: Are there any specific foods, like grapefruit or bananas, to avoid while taking Zargo?

The product information advises caution regarding potassium intake. Co-administration with potassium supplements or diuretics that conserve potassium is a documented interaction risk due to the potential for high potassium levels. Food timing is flexible.


Q: What happens if I occasionally miss a dose of Zargo?

Regulatory patient information provides specific guidance on missed doses, generally advising against taking a double dose. Patients should follow the instructions provided by their prescribing physician or refer to the specific dosing directions in the medicine leaflet.


Q: Can Zargo help reduce swelling or edema related to heart issues?

Zargo is indicated for treating high blood pressure and is sometimes used in the management of certain heart conditions. While it is not a primary diuretic, its ability to reduce strain on the cardiovascular system can contribute to the overall management of fluid retention related to these conditions.


Q: What should I do if I experience an unexpected rash while taking Zargo?

Any unexplained rash can be a symptom of a serious allergic reaction (hypersensitivity) which requires immediate medical attention. The official safety information warns of this possibility, though rash is not listed as a common, isolated side effect.


Q: Does Zargo cause joint pain or back pain in some users?

Official product information notes that back pain is one of the most common adverse reactions reported in clinical trials. However, joint pain (arthralgia) is not listed among the commonly reported side effects.


Q: Can Zargo affect the way my kidneys function over time?

The drug is indicated to slow the progression of kidney disease in people with Type 2 diabetes. However, in other patients, particularly those with pre-existing kidney or severe heart issues, it may sometimes adversely affect kidney function, requiring regular monitoring.


Q: Is it normal to feel a 'pins and needles' sensation or numbness in the hands or feet while on Zargo?

Official adverse reaction reports indicate that a 'pins and needles' sensation (paresthesia) is a less common side effect reported by some patients during clinical trials.


Q: Does Zargo have known interactions with common cold or flu medications?

Zargo is known to interact with NSAIDs (like ibuprofen), which are often found in cold and flu remedies. It is important to check the ingredients of any over-the-counter medication for cold or flu to avoid potential drug interactions.


Q: How quickly would Zargo start lowering my blood pressure after the first dose?

Regulatory information indicates that Losartan is absorbed quickly after taking it. The initial lowering of blood pressure typically begins as early as one to four hours after the first dose, when the drug and its active form reach their peak concentrations in the blood.


Q: Why should I limit my alcohol intake while taking Zargo?

Caution is advised regarding alcohol intake because it can lower blood pressure on its own. Taking Zargo along with alcohol may have an additive effect, increasing the risk of low blood pressure (hypotension) and associated symptoms like dizziness.

--ENSURE CONSISTENCY WITH PREVIOUS CONTENT. NO CHANGES. NO INACCURACY--

Q: Is Zargo used for any conditions other than high blood pressure, heart failure, and kidney protection?

Official US regulatory labeling limits Zargo’s indicated uses to the treatment of hypertension, the reduction of stroke risk in hypertensive patients with Left Ventricular Hypertrophy (LVH), and the treatment of diabetic kidney disease.


Q: Can Zargo cause a stuffy nose or upper respiratory infection?

Yes, regulatory documents list both upper respiratory infection and nasal congestion (stuffy nose) among the common adverse reactions reported in clinical trials.


Q: What precautions should I take regarding exercise and extreme heat while on Zargo?

Since Zargo lowers blood pressure, there is a general precaution regarding conditions that may cause low blood volume, such as dehydration. Extreme heat and heavy exercise can lead to fluid loss, and patients are generally advised to remain adequately hydrated during these periods.


Q: How is Zargo metabolized by the body?

Official product information states that Losartan is well-absorbed and then undergoes a chemical process (metabolism) in the liver. This process converts it into its active form, known as a carboxylic acid metabolite, primarily through the CYP450 enzyme system.


Q: What are the signs of high potassium levels (hyperkalemia) I should watch for while taking Zargo?

Symptoms of high blood potassium levels (hyperkalemia) can include unusual tiredness, muscle weakness, or a slow and irregular heartbeat. Because Zargo can increase potassium levels, regular monitoring is necessary to check for this risk.


Q: What is the long-term data on the safety profile of Zargo?

Long-term safety information is available from the extended periods of major clinical trials. In these studies, Zargo was generally well-tolerated over several years of use, including in specific populations like pediatric patients with diabetic kidney disease.


Q: Does the brand name Zargo offer a combination pill with another drug?

The active ingredient in Zargo, Losartan, is often used in fixed-dose combination products with a diuretic, such as Hydrochlorothiazide, to treat hypertension. This combination is a separate prescription product used when two different mechanisms are required to lower blood pressure.


Q: Is Zargo a medicine that can be crushed or chewed if swallowing is difficult?

Zargo is supplied as a film-coated oral tablet, which is typically intended to be swallowed whole. There are no instructions in the regulatory labeling that state the tablets may be crushed or chewed to aid swallowing.

How should Zargo be stored and disposed of?

How to Store and Dispose of Zargo (Losartan Potassium)

Formulation Required Storage Condition Stability/Handling Rules
Oral Tablet Store at controlled room temperature (20 C to 25 C). Keep in the container it came in, tightly closed, protected from excess heat, light, and moisture. Do not freeze.
Oral Suspension Store refrigerated (2 C to 8 C). The compounded liquid must be discarded after 28 days from the date of preparation. Must be kept from freezing.

All forms of Zargo must be kept out of the sight and reach of children.

Disposal of unused or expired Zargo must follow official guidelines. Do not flush the medication down a toilet or pour it down a sink. Unused products should be disposed of by following local pharmaceutical take-back programs or by using the official household trash procedure (mixing with an undesirable substance in a sealed container).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zargo found in:

A-Z Index: